Safety and infectivity of two doses of live-attenuated recombinant cold-passaged human parainfluenza type 3 virus vaccine rHPIV3cp45 in HPIV3-seronegative young children

Vaccine

Volumn 31, Issue 48, 2013, Pages 5706-5712

  Englund, Janet A ^a   Karron, Ruth A ^b   Cunningham, Coleen K ^c   La Russa, Philip ^d   Melvin, Ann ^a   Yogev, Ram ^e   Handelsman, Ed ^f   Siberry, George K ^g   Thumar, Bhavanji ^b   Schappell, Elizabeth ^b   Bull, Catherine V ^a   Chu, Helen Y ^a   Schaap Nutt, Anne ^f   Buchholz, Ursula ^f   Collins, Peter L ^f   Schmidt, Alexander C ^f   Melvin, Ann J ^h   Marillo, Linda ⁱ   Petzold, Elizabeth ^j   Sato, Paul ^f   Thomas, Joycelyn ⁱ   Dragavon, Joan ^a   more..

^a UNIVERSITY OF WASHINGTON   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d Och Spine at New York Presbyterian Hospitals   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^g EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^h SEATTLE CHILDREN S HOSPITAL   (United States)

ⁱ FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^j SOCIAL AND SCIENTIFIC SYSTEMS INC   (United States)

more..

Author keywords

Live attenuated vaccine; Parainfluenza; Pediatric vaccine; Recombinant virus vaccine

Indexed keywords

ANTIBIOTIC AGENT; ANTIBODY; LIVE VACCINE; PARAINFLUENZA VACCINE; PLACEBO; STEROID;

ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; COUGHING; DOUBLE BLIND PROCEDURE; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INFANT; LOWER RESPIRATORY TRACT; LOWER RESPIRATORY TRACT INFECTION; MALE; OTITIS MEDIA; PARAINFLUENZA VIRUS 3; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SIDE EFFECT; TISSUE CULTURE; UPPER RESPIRATORY TRACT; VACCINATION; VIRUS SHEDDING;

LIVE-ATTENUATED VACCINE; PARAINFLUENZA; PEDIATRIC VACCINE; RECOMBINANT VIRUS VACCINE;

ANTIBODIES, VIRAL; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; INFANT; MALE; NASAL CAVITY; PARAINFLUENZA VACCINES; PARAINFLUENZA VIRUS 3, HUMAN; PLACEBOS; RESPIROVIRUS INFECTIONS; VACCINATION; VACCINES, ATTENUATED; VACCINES, SYNTHETIC;

EID: 84886953659     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.09.046     Document Type: Article

References (27)

1. Glezen W.P., Frank A.L., Taber L.H., Kasel J.A. Parainfluenza virus type 3: seasonality and risk of infection and reinfection in young children. J Infect Dis 1984, 150(6):851-857.
2. Chanock R.M., Murphy B.R., Collins P.L. Parainfluenza viruses. Fields virology 2001, 1341-1379. Lippincott Williams & Wilkins, Philadelphia. 4th ed. D.M. Knipe, P.M. Howley, D.E. Griffin, R.A. Lamb, M.A. Martin, B. Roizman (Eds.).
3. Weinberg G.A., Hall C.B., Iwane M.K., Poehling K.A., Edwards K.M., Griffin M.R., et al. Parainfluenza virus infection of young children: estimates of the population-based burden of hospitalization. J Pediatr 2009, 154(5):694-699.
4. Glezen W.P., Greenberg S.B., Atmar R.L., Piedra P.A., Couch R.B. Impact of respiratory virus infections on persons with chronic underlying conditions. JAMA 2000, 283(4):499-505.
5. Peck A.J., Englund J.A., Kuypers J., Guthrie K.A., Corey L., Morrow R., et al. Respiratory virus infection among hematopoietic cell transplant recipients: evidence for asymptomatic parainfluenza virus infection. Blood 2007, 110(5):1681-1688.
6. Weinberg A., Lyu D.M., Li S., Marquesen J., Zamora M.R. Incidence and morbidity of human metapneumovirus and other community-acquired respiratory viruses in lung transplant recipients. Transpl Infect Dis 2010, 12(4):330-335.
7. Schmidt A.C. Progress in respiratory virus vaccine development. Semin Respir Crit Care Med 2011, 32(4):527-540.
8. Karron R.A., Belshe R.B., Wright P.F., Thumar B., Burns B., Newman F., et al. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants. Pediatr Infect Dis J 2003, 22(5):394-405.
9. Schmidt A.C., Schaap-Nutt A., Bartlett E.J., Schomacker H., Boonyaratanakornkit J., Karron R.A., et al. Progress in the development of human parainfluenza virus vaccines. Expert Rev Respir Med 2011, 5(4):515-526.
10. Bernstein D.I., Falloon J., Yi T. A randomized, double-blind, placebo-controlled, phase 1/2a study of the safety and immunogenicity of a live, attenuated human parainfluenza virus type 3 vaccine in healthy infants. Vaccine 2011, 29(40):7042-7048.
11. Durbin A.P., Karron R.A. Progress in the development of respiratory syncytial virus and parainfluenza virus vaccines. Clin Infect Dis 2003, 37(12):1668-1677.
12. Ambrose C.S., Wu X., Knuf M., Wutzler P. The efficacy of intranasal live attenuated influenza vaccine in children 2 through 17 years of age: a meta-analysis of 8 randomized controlled studies. Vaccine 2012, 30(5):886-892.
13. Karron R.A., Wright P.F., Hall S.L., Makhene M., Thompson J., Burns B.A., et al. A live attenuated bovine parainfluenza virus type 3 vaccine is safe, infectious, immunogenic, and phenotypically stable in infants and children. J Infect Dis 1995, 171(5):1107-1114.
14. Karron R.A., Thumar B., Schappell E., Surman S., Murphy B.R., Collins P.L., et al. Evaluation of two chimeric bovine-human parainfluenza virus type 3 vaccines in infants and young children. Vaccine 2012, 30(26):3975-3981.
15. Greenberg D.P., Walker R.E., Lee M.S., Reisinger K.S., Ward J.I., Yogev R., et al. A bovine parainfluenza virus type 3 vaccine is safe and immunogenic in early infancy. J Infect Dis 2005, 191(7):1116-1122.
16. Schmidt A.C., McAuliffe J.M., Huang A., Surman S.R., Bailly J.E., Elkins W.R., et al. Bovine parainfluenza virus type 3 (BPIV3) fusion and hemagglutinin-neuraminidase glycoproteins make an important contribution to the restricted replication of BPIV3 in primates. J Virol 2000, 74(19):8922-8929.
17. Gomez M., Mufson M.A., Dubovsky F., Knightly C., Zeng W., Losonsky G. Phase-I study MEDI-534, of a live, attenuated intranasal vaccine against respiratory syncytial virus and parainfluenza-3 virus in seropositive children. Pediatr Infect Dis J 2009, 28(7):655-658.
18. Belshe R.B., Newman F.K., Tsai T.F., Karron R.A., Reisinger K., Roberton D., et al. Phase 2 evaluation of parainfluenza type 3 cold passage mutant 45 live attenuated vaccine in healthy children 6-18 months old. J Infect Dis 2004, 189(3):462-470.
19. Crookshanks F.K., Belshe R.B. Evaluation of cold-adapted and temperature-sensitive mutants of parainfluenza virus type 3 in weanling hamsters. J Med Virol 1984, 13(3):243-249.
20. Crookshanks-Newman F.K., Belshe R.B. Protection of weanling hamsters from experimental infection with wild-type parainfluenza virus type 3 (para 3) by cold-adapted mutants of para 3. J Med Virol 1986, 18(2):131-137.
21. Belshe R.B., Newman F.K., Anderson E.L., Wright P.F., Karron R.A., Tollefson S., et al. Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children. J Infect Dis 2004, 190(12):2096-2103.
22. Madhi S.A., Cutland C., Zhu Y., Hackell J.G., Newman F., Blackburn N., et al. Transmissibility, infectivity and immunogenicity of a live human parainfluenza type 3 virus vaccine (HPIV3cp45) among susceptible infants and toddlers. Vaccine 2006, 24(13):2432-2439.
23. Karron R.A., Wright P.F., Newman F.K., Makhene M., Thompson J., Samorodin R., et al. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in healthy infants and children. J Infect Dis 1995, 172(6):1445-1450.
24. Skiadopoulos M.H., Surman S., Tatem J.M., Paschalis M., Wu S.L., Udem S.A., et al. Identification of mutations contributing to the temperature-sensitive, cold-adapted, and attenuation phenotypes of the live-attenuated cold-passage 45 (cp45) human parainfluenza virus 3 candidate vaccine. J Virol 1999, 73(2):1374-1381.
25. Karron R.A., Casey R., Thumar B., Surman S., Murphy B.R., Collins P.L., et al. The cDNA-derived investigational human parainfluenza virus type 3 vaccine rcp45 is well tolerated, infectious, and immunogenic in infants and young children. Pediatr Infect Dis J 2011, 30(10):e186-e191.
26. Siberry G.K., Diener-West M., Schappell E., Karron R.A. Comparison of temple temperatures with rectal temperatures in children under two years of age. Clin Pediatr (Phila) 2002, 41(6):405-414.
27. Karron R.A., Makhene M., Gay K., Wilson M.H., Clements M.L., Murphy B.R. Evaluation of a live attenuated bovine parainfluenza type 3 vaccine in two- to six-month-old infants. Pediatr Infect Dis J 1996, 15(8):650-654.